Tanabe Seiyaku Co., Ltd. (Osaka, Japan, President; Natsuki Hayama) announced today that it concluded a license agreement with ISTA Pharmaceuticals, Inc. (California, U.S.A.) regarding exclusive North American rights to develop, manufacture, and market nasal formulation of bepotastine besilate which is an active ingredient of the antiallergic product, Talion®, for the treatment or prevention of allergic and nonallergic-related symptoms.

Bepotastine besilate was originally synthesized and identified by Ube Industries, Ltd.(Ube, Yamaguchi, President; Hiroaki Tamura). Ube and Tanabe jointly developed, and Tanabe has marketed it as Talion® Tablets for allergic disorders in Japan since 2000. This July, Tanabe has launched orally disintegrating tablet, Talion® OD Tablets. Bepotastine besilate for ophthalmic use has currently been developing as allergic conjunctivitis in Japan by Senju Seiyaku Co., Ltd. (Osaka, Japan, President; Yukoh Yoshida) and by ISTA in North America.

Contact for further information on this press release:
Tanabe Seiyaku Co., Ltd., Corporate Communications Division
Phone: 06-6205-5211    Fax: 06-6205-5105